322 related articles for article (PubMed ID: 8675091)
21. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC).
Stinton LM; Bentow C; Mahler M; Norman GL; Eksteen B; Mason AL; Kaplan GG; Lindkvist B; Hirschfield GM; Milkiewicz P; Cheung A; Janssen HL; Fritzler MJ
PLoS One; 2014; 9(11):e112877. PubMed ID: 25397578
[TBL] [Abstract][Full Text] [Related]
22. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.
Schwarze C; Terjung B; Lilienweiss P; Beuers U; Herzog V; Sauerbruch T; Spengler U
Clin Exp Immunol; 2003 Aug; 133(2):283-9. PubMed ID: 12869036
[TBL] [Abstract][Full Text] [Related]
23. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders.
Kallenberg CG; Mulder AH; Tervaert JW
Am J Med; 1992 Dec; 93(6):675-82. PubMed ID: 1466365
[TBL] [Abstract][Full Text] [Related]
24. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.
Terjung B; Spengler U; Sauerbruch T; Worman HJ
Gastroenterology; 2000 Aug; 119(2):310-22. PubMed ID: 10930366
[TBL] [Abstract][Full Text] [Related]
25. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives.
Radice A; Vecchi M; Bianchi MB; Sinico RA
Clin Exp Rheumatol; 2000; 18(6):707-12. PubMed ID: 11138332
[TBL] [Abstract][Full Text] [Related]
26. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
27. Antineutrophil nuclear antibodies (ANNA) in primary biliary cirrhosis: their prevalence and antigen specificity.
Orth T; Gerken G; Meyer Zum Büschenfelde KH; Mayet WJ
Z Gastroenterol; 1997 Feb; 35(2):113-21. PubMed ID: 9066101
[TBL] [Abstract][Full Text] [Related]
28. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis.
Pokorny CS; Norton ID; McCaughan GW; Selby WS
J Gastroenterol Hepatol; 1994; 9(1):40-4. PubMed ID: 8155865
[TBL] [Abstract][Full Text] [Related]
29. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis.
Karlsen TH; Boberg KM; Vatn M; Bergquist A; Hampe J; Schrumpf E; Thorsby E; Schreiber S; Lie BA;
Genes Immun; 2007 Apr; 8(3):275-8. PubMed ID: 17301827
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis.
Roozendaal C; Horst G; Pogány K; van Milligen de Wit AW; Kleibeuker JH; Haagsma EB; Limburg PC; Kallenberg CG
Adv Exp Med Biol; 1998; 443():313-9. PubMed ID: 9781375
[TBL] [Abstract][Full Text] [Related]
31. IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis.
Jayne DR; Weetman AP; Lockwood CM
Clin Exp Immunol; 1991 Jun; 84(3):476-81. PubMed ID: 2044229
[TBL] [Abstract][Full Text] [Related]
32. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.
Holland M; Hewins P; Goodall M; Adu D; Jefferis R; Savage CO
Clin Exp Immunol; 2004 Oct; 138(1):183-92. PubMed ID: 15373923
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique.
Lo SK; Fleming KA; Chapman RW
Gut; 1992 Oct; 33(10):1370-5. PubMed ID: 1446862
[TBL] [Abstract][Full Text] [Related]
34. Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis.
Lampinen M; Fredricsson A; Vessby J; Martinez JF; Wanders A; Rorsman F; Carlson M
J Leukoc Biol; 2018 Jul; 104(1):173-183. PubMed ID: 29603385
[TBL] [Abstract][Full Text] [Related]
35. [Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease].
García-Herola A; Nos P; Hoyos M; Hinojosa J; Molés JR; Pascual S; Bustamante M; Sánchez Cuenca JM; Carmona E; Ponce J; Berenguer J
Gastroenterol Hepatol; 1998 Apr; 21(4):169-73. PubMed ID: 9633176
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.
Seibold F; Weber P; Klein R; Berg PA; Wiedmann KH
Gut; 1992 May; 33(5):657-62. PubMed ID: 1612483
[TBL] [Abstract][Full Text] [Related]
37. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease.
Mahler M; Bogdanos DP; Pavlidis P; Fritzler MJ; Csernok E; Damoiseaux J; Bentow C; Shums Z; Forbes A; Norman GL
Clin Chim Acta; 2013 Sep; 424():267-73. PubMed ID: 23806819
[TBL] [Abstract][Full Text] [Related]
38. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.
Peen E; Almer S; Bodemar G; Rydén BO; Sjölin C; Tejle K; Skogh T
Gut; 1993 Jan; 34(1):56-62. PubMed ID: 8432453
[TBL] [Abstract][Full Text] [Related]
39. [Antibodies to neutrophilic granulocytes (p-ANCA): a further indication for a common origin of ulcerative colitis and primary sclerosing cholangitis?].
Jahn HU; Zeitz M
Z Gastroenterol; 1992 Jun; 30(6):441-2. PubMed ID: 1636280
[No Abstract] [Full Text] [Related]
40. Anti-neutrophil antibodies in primary sclerosing cholangitis.
Terjung B; Worman HJ
Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):629-42. PubMed ID: 11492972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
